339 related articles for article (PubMed ID: 15564720)
1. The biology of CD20 and its potential as a target for mAb therapy.
Cragg MS; Walshe CA; Ivanov AO; Glennie MJ
Curr Dir Autoimmun; 2005; 8():140-74. PubMed ID: 15564720
[TBL] [Abstract][Full Text] [Related]
2. CD20 as a target for therapeutic type I and II monoclonal antibodies.
Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ
Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657
[TBL] [Abstract][Full Text] [Related]
3. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C
MAbs; 2012; 4(4):488-96. PubMed ID: 22647435
[TBL] [Abstract][Full Text] [Related]
4. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
Winiarska M; Bil J; Wilczek E; Wilczynski GM; Lekka M; Engelberts PJ; Mackus WJ; Gorska E; Bojarski L; Stoklosa T; Nowis D; Kurzaj Z; Makowski M; Glodkowska E; Issat T; Mrowka P; Lasek W; Dabrowska-Iwanicka A; Basak GW; Wasik M; Warzocha K; Sinski M; Gaciong Z; Jakobisiak M; Parren PW; Golab J
PLoS Med; 2008 Mar; 5(3):e64. PubMed ID: 18366248
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
[TBL] [Abstract][Full Text] [Related]
6. Functional role of lipid rafts in CD20 activity?
Janas E; Priest R; Malhotra R
Biochem Soc Symp; 2005; (72):165-75. PubMed ID: 15649140
[TBL] [Abstract][Full Text] [Related]
7. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
8. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Cragg MS; Glennie MJ
Blood; 2004 Apr; 103(7):2738-43. PubMed ID: 14551143
[TBL] [Abstract][Full Text] [Related]
9. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
10. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
12. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
[TBL] [Abstract][Full Text] [Related]
13. Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts.
Ringshausen I; Feuerstacke Y; Krainz P; den Hollander J; Hermann K; Buck A; Peschel C; Meyer Zum Bueschenfelde C
Cancer Res; 2010 Jun; 70(11):4292-6. PubMed ID: 20460536
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of killing by anti-CD20 monoclonal antibodies.
Glennie MJ; French RR; Cragg MS; Taylor RP
Mol Immunol; 2007 Sep; 44(16):3823-37. PubMed ID: 17768100
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy.
Borisch B; Semac I; Soltermann A; Palomba C; Hoessli DC
Verh Dtsch Ges Pathol; 2001; 85():161-6. PubMed ID: 11894393
[TBL] [Abstract][Full Text] [Related]
16. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
17. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
Harjunpää A; Junnikkala S; Meri S
Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
19. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.
Cragg MS; Morgan SM; Chan HT; Morgan BP; Filatov AV; Johnson PW; French RR; Glennie MJ
Blood; 2003 Feb; 101(3):1045-52. PubMed ID: 12393541
[TBL] [Abstract][Full Text] [Related]
20. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
